企業を読み込み中
Just reported
Q3 2026 results
From Arcutis Biotherapeutics's results release of 2026年11月4日; its quarterly report has since been filed.
Revenue
Actual
$143.9M
+45% y/y
+11% q/qGuided
—
No guide given
EPS, GAAP
Actual
$0.06
0.0% y/y
-45% q/qGuided
—
No guide given
Operating income, GAAP
Actual
$9.4M
+11% y/y
-43% q/qGuided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Arcutis Biotherapeutics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.$47.5BA+
EXELExelixis, Inc.$17BA+
JAZZJazz Pharmaceuticals plc$15.4BA
HALOHalozyme Therapeutics, Inc.$11.5BA+
TECHBIO-Techne Corp$11.4BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026年10月21日CBGraded C, now B
MCKMckesson Corporation2026年11月4日BAGraded B, now A
CVSCVS Health Corp2026年11月4日BAGraded B, now A
EWEdwards Lifesciences Corporation2026年11月4日BAGraded B, now A
BIIBBiogen Inc.2026年10月28日BAGraded B, now A
Arcutis Biotherapeutics, Inc. 自身が米国証券取引委員会（SEC）に提出した書類にもとづきます。数字は報告されたままで、1 株当たりの履歴は今日の株数基準に修正済みです。 これは事業の説明です——投資助言ではなく、売買を勧めるものでもありません。
